Nurix Therapeutics (Nasdaq:NRIX) - Aktienkurs, Nachrichten und Analyse

NRIX Aktienübersicht

NRIX grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 28.87%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 2.3% pro Jahr sinken.

Die Aktionäre wurden im vergangenen Jahr verwässert

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Nurix Therapeutics, Inc. Wettbewerber

BioCryst Pharmaceuticals

NasdaqGS:BCRX

US$1.6b

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

Recursion Pharmaceuticals

NasdaqGS:RXRX

US$1.6b

Aurinia Pharmaceuticals

NasdaqGM:AUPH

US$1.3b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Nurix Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	US$22.05
52-Wochen-Hoch	US$29.56
52-Wochen-Tief	US$5.65
Beta	2.2
11 Monat Veränderung	-16.06%
3 Monate Veränderung	-14.17%
1 Jahr Veränderung	254.50%
33 Jahre Veränderung	-26.65%
5 Jahre Veränderung	n/a
Veränderung seit IPO	15.99%

Aktuelle Nachrichten und Updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31

Recent updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

Aktionärsrenditen

	NRIX	US Biotechs	US Markt
7D	-3.8%	2.5%	2.2%
1Y	254.5%	16.1%	31.6%

Rendite im Vergleich zur Industrie: NRIX übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 16.1 erzielte.

Rendite vs. Markt: NRIX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 31.6 erzielte.

Preisvolatilität

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement	8.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: NRIX hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: NRIXDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2009	284	Arthur Sands	www.nurixtx.com

Nurix Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung von kleinen Molekülen und Zelltherapien zur Behandlung von Krebs, Entzündungen und anderen Krankheiten. Das Unternehmen entwickelt NX-2127, einen oral bioverfügbaren Bruton-Tyrosinkinase (BTK)-Abbauer für die Behandlung von rezidivierenden oder refraktären B-Zell-Malignomen; NX-5948, ein oral verfügbarer BTK-Degrader für die Behandlung von rezidivierenden oder refraktären B-Zell-Malignomen und Autoimmunkrankheiten; und NX-1607, ein oral bioverfügbarer Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) Inhibitor für immunonkologische Indikationen. Darüber hinaus entwickelt das Unternehmen NX-0479/GS-6791, einen IRAK4-Abbauhemmer für die Behandlung von rheumatoider Arthritis und anderen Entzündungskrankheiten.

Nurix Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Nurix Therapeutics im Vergleich zum Marktanteil des Unternehmens?
NRIX grundlegende Statistiken
Marktanteil	US$1.56b
Gewinn(TTM)	-US$176.98m
Umsatz(TTM)	US$56.42m

27.7x

Kurs-Umsatz-Verhältnis

-8.8x

Kurs-Gewinn-Verhältnis

Ist NRIX zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
NRIX Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$56.42m
Kosten der Einnahmen	US$204.12m
Bruttogewinn	-US$147.70m
Sonstige Ausgaben	US$29.28m
Umsatz	-US$176.98m

Zuletzt gemeldete Gewinne

Aug 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.50
Bruttomarge	-261.76%
Nettogewinnspanne	-313.65%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich NRIX auf lange Sicht entwickelt?

Historische Performance und Vergleiche

NRIX Aktienübersicht

Belohnungen

Risikoanalyse

Nurix Therapeutics, Inc. Wettbewerber

NasdaqGS:BCRX

US$1.6b

NasdaqGS:DCPH

US$2.2b

NasdaqGS:RXRX

US$1.6b

NasdaqGM:AUPH

US$1.3b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Recent updates

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Nurix: An Attractive Early-Stage Biotech Play

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Erträge & Einnahmen